mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

NCT ID: NCT03045770

Last Updated: 2017-02-07

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-02-10
• Study Completion Date: 2019-12-30

Brief Summary

The aim of this study was to compare the efficacy and safety of mFOLFOX, mFOLFIRI and FOLFPTX as first-line treatment in AGC or EGJA.

Detailed Description

In previous studies, we found that mFOLFOX(a Combination of Oxaliplatin, Fluorouracil), mFOLFIRI(a Combination of Irinotecan, Fluorouracil), FOLFPTX (a Combination of Paclitaxel, Fluorouracil) are active in patients with AGC or EGJA.This study is being done to find out which one has the best efficacy.

Conditions

Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

mFOLFOX

The mFOLFOX regimen consisted of oxaliplatin (85 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.

Group Type: EXPERIMENTAL

Fluorouracil

Intervention Type: DRUG

Fluorouracil was used as first line treatment with AGC.

Oxaliplatin

Intervention Type: DRUG

Oxaliplatin was used as first line treatment with AGC.

calcium levofolinate

Intervention Type: DRUG

Calcium levofolinate was used as first line treatment with AGC.

mFOLFIRI

The mFOLFIRI regimen consisted of irinotecan (180 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.

Group Type: EXPERIMENTAL

Fluorouracil

Intervention Type: DRUG

Fluorouracil was used as first line treatment with AGC.

Irinotecan

Intervention Type: DRUG

Irinotecan was used as first line treatment with AGC.

calcium levofolinate

Intervention Type: DRUG

Calcium levofolinate was used as first line treatment with AGC.

FOLFPTX

The FOLFPTX regimen consisted of paclitaxel (95 mg/m2) and calcium levofolinate (200 mg/m2).Subsequently, a 48-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days till progressive disease or intolerable toxicities.

Group Type: EXPERIMENTAL

Fluorouracil

Intervention Type: DRUG

Fluorouracil was used as first line treatment with AGC.

Paclitaxel

Intervention Type: DRUG

Paclitaxel was used as first line treatment with AGC.

calcium levofolinate

Intervention Type: DRUG

Calcium levofolinate was used as first line treatment with AGC.

Interventions

Fluorouracil

Fluorouracil was used as first line treatment with AGC.

Intervention Type: DRUG

Oxaliplatin

Oxaliplatin was used as first line treatment with AGC.

Intervention Type: DRUG

Irinotecan

Irinotecan was used as first line treatment with AGC.

Intervention Type: DRUG

Paclitaxel

Paclitaxel was used as first line treatment with AGC.

Intervention Type: DRUG

calcium levofolinate

Calcium levofolinate was used as first line treatment with AGC.

Intervention Type: DRUG

Other Intervention Names

5-FU; OXA; CPT-11; PTX

Eligibility Criteria

Inclusion Criteria

1. Age：18~70years.

2. Subjects with Histologically or cytologically confirmed advanced or metastatic gastric cancer or adenocarcinoma of gastroesophageal junction.

3. First-line treatment patients.

4. subjects with at least one measurable lesion as defined by RECIST (version 1.1).

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. Survival expectation≥ 3 months.

7. No serious concomitant diseases(including heart,lung,liver jaundice or gastrointestinal obstruction and so on ).

8. Adequate organ functions defined as indicated below： （1）Adequate bone marrow function, defined as: (no blood transfusion within 14 days)

1. Hemoglobin (Hb)≥80g/L，

2. White blood count (WBC)≥3.5×109/L

3. Absolute neutrophil count (ANC)≥1.5×109/L，

4. Platelet count (PLT)≥75×109/L； （2）Adequate liver function, defined as:

<!-- -->

1. Bilirubin ≤1.5×the upper limit of normal (ULN)

2. Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) ≤3.0×(ULN), Glutamyl transpeptidase(GGT)≤2.5×(ULN), (When liver metastases, ALT or AST and GPT <5.0×(ULN)).

3. serum creatinine ≤1.0×（ULN）, or creatinine clearance > 50 mL/min( calculated per the Cockcroft and Gault formula)

9. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, Females of childbearing potential must agree to use a highly effective method of contraception throughout the entire study period and for 8 weeks after study drug discontinuation. Male subjects must have had a successful vasectomy or they and their female partners must meet the criteria above (i.e.not of childbearing potential or practicing highly effective contraception throughout the study period and for 8 weeks after study drug discontinuation).

10. Subjects provided written informed consent before participating,Willing and able to comply with all aspects of the protocol.

Exclusion Criteria

1. Females are lactating or pregnant at Screening or Baseline.

2. Patients with other active malignancy (except for definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix).

3. Patients who have received previous pre- or post-operative chemotherapy or chemoradiation are ineligible if therapy was completed less than 6 months prior to study registration. Patients must have recovered from adverse events from any previous therapy.

4. Patients with brain or central nervous system metastases, including leptomeningeal disease.

5. Significant cardiac disease as defined as:unstable angina, New York Heart Association (NYHA) grade II or greater, congestive heart failure, history of myocardial infarction within 6 months Evidence of bleeding diathesis or coagulopathy.

6. History of a stroke or CVA within 6 months.

7. Inability to comply with study and/or follow-up procedures.

8. Patients with any other condition that in the opinion of the investigator would preclude his/her participation in a clinical study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fujian Cancer Hospital

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jianwei Yang

Role: PRINCIPAL_INVESTIGATOR

Fujian Cancer Hospital

Locations

Jianwei Yang

Fuzhou, Fujian, China

Countries

China

Central Contacts

Jianwei Yang

Role: CONTACT

swzcq62@163.com

008613805097959

Sha Huang

Role: CONTACT

huangsha0210@163.com

008613763820570

Other Identifiers

FJG201701

Identifier Type: -

Identifier Source: org_study_id